IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Community-Acquired Pneumonia (CAP)
Conditions
Community-Acquired Pneumonia (CAP)
Trial Timeline
Jan 1, 2001 → Jun 1, 2002
NCT ID
NCT00035347About IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin
IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin is a approved stage product being developed by Pfizer for Community-Acquired Pneumonia (CAP). The current trial status is completed. This product is registered under clinical trial identifier NCT00035347. Target conditions include Community-Acquired Pneumonia (CAP).
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035347 | Approved | Completed |
Competing Products
9 competing products in Community-Acquired Pneumonia (CAP)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONO-5046Na + ONO-5046Na | Ono Pharmaceutical | Phase 2 | 52 |
| Ceftaroline + Ceftriaxone | Pfizer | Phase 3 | 76 |
| Azithromycin microspheres 2.0 single dose | Pfizer | Phase 3 | 76 |
| Azithromycin SR | Pfizer | Phase 3 | 76 |
| Azithromycin SR + Amoxiclav | Pfizer | Pre-clinical | 22 |
| tigecycline | Pfizer | Phase 3 | 76 |
| Tigecycline + Levofloxacin | Pfizer | Phase 3 | 76 |
| Omadacycline + Moxifloxacin | Zai Lab | Phase 3 | 72 |
| ceftobiprole medocaril + IV standard-of-care cephalosporin | Basilea Pharmaceutica | Phase 3 | 72 |